Tradestie Institutional Equity Comparison Engine
VIVS vs ESLA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ESLA Overall Edge
ESLA Captures Institutional Edge (3โ0 Pillars ยท 6โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Estrella Immunopharma, Inc. Common Stock (ESLA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VIVS trades at N/M Forward P/E with -10117.0% operating margin (-51.4% YoY revenue) versus ESLA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against ESLA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
VIVS N/M vs ESLA N/M Fwd P/E
Growth & Margin Winner
ESLA
Op Margin -10117.0% vs 0.0% ยท YoY -51.4% vs +0.0%
Momentum & Technical Winner
ESLA
1Y -87.0% vs -81.3% ยท 52W Pos 5% vs 5%
Options & Structure Winner
ESLA
BREAKDOWN (N/A IV) vs UNCLASSIFIED (N/A IV)
VIVS
NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap
$2.4M
1M Return
+64.69%
1Y Return
-86.99%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 5.0
Fund 38.0
Flow 50.0
Mom 50.0
ESLA
NASDAQ
Estrella Immunopharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.34
+2.25% 1D
Market Cap
$14.6M
1M Return
-38.11%
1Y Return
-81.3%
Forward P/E
N/M
Unified AI Score
46.0 / 100
HOLD
Tech 50.0
Fund 51.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VIVS -86.99%
ESLA -81.3%
Spread: +5.69 pp (ESLA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
VIVS TTM Op. Margin: -10117.0%
ESLA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VIVS vs ESLA. Trailing 12-month operating profitability (VIVS -10117.0% vs ESLA 0.0%) and valuation multiples (VIVS N/M vs ESLA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VIVS | ESLA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.4M | $14.6M | Larger Scale | ESLA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -51.4% | +0.0% | Higher Growth | ESLA |
| Operating Margin (TTM) Profitability | -10117.0% | 0.0% | Higher Margin | ESLA |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -343.1% | -268.5% | Higher ROE | ESLA |
| 52-Week Range Position Momentum | 5% ($0โ$3) | 5% ($0โ$2) | Stronger Trend | Tie |
| Beta / 30D Volatility Risk Regime | 0.83ฮฒ ยท 480% Vol | 1.56ฮฒ ยท 339% Vol | Lower Realized Risk | ESLA |
| Unified Institutional Score Composite Signal | 36.8 / 100 (SELL) | 46.0 / 100 (HOLD) | Higher Composite | ESLA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VIVS vs ESLA Buy Guide
VIVS
BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ESLA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VIVS nor ESLA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.